In this commentary, Robert Rosenson, MD, explains that PCSK9 inhibitors may be a useful alternative therapy in lowering LDL cholesterol in individuals who are unable to tolerate statins at the doses...
In this commentary, Dr Seth Martin explains the updates to the Friedewald estimation that he hopes more labs will adopt to ensure LDL assessments are as accurate as possible.
